A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
Latest Information Update: 30 Jun 2023
At a glance
- Drugs RC 108 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors RemeGen
- 26 Jun 2023 According to an Innovent Biologics media release, RemeGen received approval from the National Medical Products Administration to conduct Phase 1 clinical trials of RC108 targeting c-MET-positive advanced solid tumors in China.
- 18 Apr 2021 Status changed from not yet recruiting to recruiting.
- 10 Nov 2020 New trial record